Long term relative survival of haematopoietic stem cell transplant recipients

This project will review the 2002 to 2014 registry data, examining the patient and transplant characteristics and mortality outcomes after 2 and 5 years post–transplant. Comparisons will be made with the general population using relative survival methods.

Paediatric αβ haploidentical transplantation (Pαβlo)

This is a prospective phase II study of the safety and cost-effectiveness of paediatric patients receiving TCR α+β+/CD19+ cell depleted haploidentical donor stem cell transplantation compared to those receiving an alternate donor haematopoietic stem cell transplant.

Non-relapse mortality in unrelated donor transplants

The number of unrelated donor transplants performed in Australia and New Zealand has increased markedly in the past 15 years. This retrospective analysis will examine the impact of changes in practice over this time, such as greater availability of fully matched donors, use of reduced intensity conditioning, graft vs host disease prophylaxis and supportive care.

Haploidentical peripheral blood stem cell transplantation with post-transplant cyclophosphamide as GVHD prophylaxis

This phase II study will involve 6 transplant centres from Australia and New Zealand and is the ABMTRR's first prospective study. It is supported by a grant from the Arrow Bone Marrow Transplant Foundation, which enabled database enhancements to streamline data management for this and future registry studies.

Effect of donor age on unrelated donor haematopoietic cell transplant outcome

This study will seek to determine the effect of donor age on the outcome of unrelated donor haematopoietic cell transplants in Australia, measured by engraftment, graft-versus-host disease, overall survival and disease-free survival.

T-cell depletion in unrelated donor transplants: the UDALL study

This retrospective analysis is investigating the effect of T-cell depletion on unrelated donor transplant outcomes for adults transplanted for acute lymphoblastic leukaemia in Australia and New Zealand.

Allogeneic transplants for paediatric patients with AML in CR2

ANZCHOG is supporting this retrospective project investigating the impact of re-induction chemotherapy and minimal residual disease on transplant outcomes in children transplanted for relapsed AML.

Conditioning for allogeneic transplants for paediatric patients with ALL

This ANZCHOG supported project will investigate the effect of the addition of thiotepa to total body irradiation and cyclophosphamide conditioning regimens, to determine whether there is any benefit to the use of thiotepa in conditioning for children transplanted for acute lymphoblastic leukaemia.

The effect of genotype on transplant outcomes

This laboratory study is being done by Westmead Institute for Medical Research in conjunction with the ABMDR, analysing donor-recipient tissue samples. The ABMTRR is providing transplant outcome data so that the researchers can determine any effect of genotype on transplant outcome.

Transplant centre capacity

In Australia and New Zealand, numbers of both autologous and allogeneic haematopoietic cell transplants (HCT) have increased consistently in recent years while the number of centres performing HCT has remained relatively constant. For this study we collected details on transplant physicians and relevant indicators of capacity and performance, in order to understand the current capacity of HCT centres in regard to staffing resources and bed numbers compared to the number of HCT performed.

UpdateThank you for your support at HAA 2017, we hope to see you at Blood 2018 in Brisbane